FindTrial
Sign In

Studying the Safety and Benefits of Oral Semaglutide for People with Diabetes and Obesity.

Safety and Efficacy of Oral Semaglutide in Patients with Type 2 Diabetes and Obesity: An Observational Study at a Tertiary Care Hospital. - nil

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2025/04/085464
Enrollment
45
Registered
2025-04-23
Start date
Unknown
Completion date
Unknown
Last updated
2025-04-28

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E116- Type 2 diabetes mellitus with other specified complications

Interventions

Intervention1: NA: NA

Sponsors

Sri Ramachandra Institute Of Higher Education and Research
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: 1 Adults more than 18 years diagnosed with Type 2 diabetes with HbA1C 7 percent to 10 percent. 2 BMI more than 27 kg per m2 indicative of obesity.

Exclusion criteria

Exclusion criteria: 1 Type 1 diabetes or other severe comorbidities such as renal or liver disease. 2 Pregnant or breastfeeding women. 3 Patients currently on other GLP 1 receptor agonists insulin or weight loss medications.

Design outcomes

Primary

MeasureTime frame
Change in HbA1c (%) from baseline to the end of the study (to assess glycemic control). Change in body weight (kg or % reduction) from baseline to the end of the study (to evaluate weight loss). Timepoint: 1 Month—

Secondary

MeasureTime frame
Safety & Tolerability: Incidence of adverse events & Serious Adverse Events. Gastrointestinal side effects such as nausea, vomiting, diarrhea. Hypoglycemia events. Timepoint: 1 Month—

Countries

India

Contacts

Public ContactDr Adlyne Reena Asirvatham

Sri Ramachandra Institute of Higher Education and Research

amb@sriramachandra.edu.in9488588735

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026